U.S., July 28 -- ClinicalTrials.gov registry received information related to the study (NCT07728942) titled 'SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors' on July 15.
Brief Summary: This is a Phase 1 study evaluating the feasibility of using SLR-108 for positron-emission tomography (PET) imaging of metastatic solid tumors.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Metastatic Solid Tumors
Intervention:
DRUG: SLR-108
SLR-108 is an antibody-radionuclide conjugate.
DRUG: SLX-1411
SLX-1411 is a non-radiolabeled antibody.
Recruitment Status: RECRUITING
Sponsor: Solve Therapeutics
Published by HT Digital Content Services with permission from Health Daily Digest....